Biology of Human Tumors Decreased Expression of miR 216 a Contributes to Non – Small-Cell Lung Cancer Progression

Ren-Tao Wang,Meng Xu,Cheng-Xiong Xu,Zhi-Gang Song,Hua Jin
2014-01-01
Abstract:Purpose:The aimof the present study is to investigate the role andmechanismofmiR216a innon–smallcell lung cancer (NSCLC). Experimental Design: The expression of miR216a in NSCLC cell lines and from NSCLC patient specimens was measured by real-time qRT-PCR. The correlation between gene expression and patient survival was analyzed using Kaplan–Meier methods. The effects of miR216a on NSCLC cell growth and metastasis were examined both in vitro and in vivo by overexpressing or inhibiting miR216a. Finally, the effect of miR216a on chemoresistance was investigated by MTT assay and flow cytometry. Results:miR216a expressionwasdownregulated in specimens frompatientswithNSCLCcomparedwith corresponding nontumor lung tissues. Clinical data indicate that decreasedmiR216a expression is inversely correlated with cancer stage, metastasis, and poor survival in patients with NSCLC. Our data also show that overexpression of miR216a suppresses NSCLC cell growth and metastasis, and enhances cisplatin-induced cell growth inhibition and apoptosis. In contrast, inhibition of miR216a stimulates NSCLC cell growth and metastasis, and suppresses cisplatin-induced cell growth inhibition and apoptosis. Furthermore, we demonstrate that miR216a exerts its role by directly targeting eIF4B and ZEB1. Conclusion:Our findings suggest thatmiR216a is a cancer suppressormiRNA and that overexpression of miR216a is a novel NSCLC treatment strategy. In addition, our clinical data indicate that miR216amay be a useful biomarker for predicting NSCLC progression. Clin Cancer Res; 20(17); 4705–16. 2014 AACR.
What problem does this paper attempt to address?